The makers of the antibody-based cancer drug Erbitux have settled a patent dispute with Israeli researchers who claimed to have invented the process for making the drug. Last year, Yeda Research and Development, the tech transfer office of the Weizmann Institute, sued ImClone and Sanofi-Aventis over the Erbitux patent. (The patent was owned by the latter and licensed by the former.) The dispute centered on a long-standing argument between Yale researcher linkurl:Joseph Schlessinger;http://www.the-scientist.com/article/display/15391/ and Weizmann researcher Michael Sela over who had conceived of the patent claims, which describe combining antibodies and chemotherapy to treat cancer. A federal judge linkurl:ruled;http://www.usatoday.com/money/industries/health/drugs/2006-09-14-imclone-usat_x.htm last September that Sela and two Weizmann colleagues were the patent's true inventors. (Disclosure: Schlessinger is an editorial advisory boardmember of The Scientist.) According to a settlement linkurl:announced;http://phx.corporate-ir.net/phoenix.zhtml?c=97689&p=irol-newsArticle&ID=1085268&highlight= by ImClone on Friday (December 7), ImClone agreed that Yeda is the sole owner of the patent's US version, and that Yeda...
Chronicle of Higher Education
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!